A phase 1b/2 study of safety and efficacy of MLN0128 (Dual TORC 1/2 Inhibitor) in combination withexemestane or fulvestrant therapy in postmenopausal women with ER+/HER2- advanced or metastatic breast cancer
|Effective start/end date||5/1/14 → 5/30/21|
- MILLENNIUM PHARMACEUTICALS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.